Wobble Genomics Appoints Dr. Dietrich A. Stephan as Chairman of the Board

Wobble Genomics Welcomes Dr. Dietrich Stephan as Chairman

Wobble Genomics, a cutting-edge biotechnology firm focused on improving cancer treatment through advanced diagnostics, has officially welcomed Dr. Dietrich A. Stephan as the new Chairman of the Board of Directors. This strategic appointment is expected to significantly bolster that company's mission to enhance cancer diagnostic methods and therapy selection.

Established with the goal of advancing outcomes for individuals battling cancer, Wobble Genomics utilizes an innovative ultra-sensitive cell-free RNA (cfRNA) liquid biopsy diagnostic platform. Dr. Stephan, who has a proven track record in scaling biotech companies, joins during a pivotal time as Wobble emerges from stealth mode.

In a statement regarding his new position, Dr. Stephan expressed his enthusiasm for the company’s proprietary cfRNA technology, which he notes holds greater sensitivity compared to existing liquid biopsy methods. This technology could potentially transform the landscape of cancer diagnosis by providing precise information about tumor biology, allowing for earlier detection, localization, monitoring of therapy response, and even recurrence of the disease—all achievable with a simple blood test that can be easily repeated throughout a patient’s treatment journey.

Dr. Stephan emphasized that these features empower healthcare providers to make informed decisions regarding therapy selection, whether that involves antibody-drug conjugates or personalized cancer vaccines. He stated, “Wobble Genomics' capabilities open new horizons for enhancing patient outcomes, particularly in cases of metastatic cancer where tumor profiling may not be possible.” The role of cfRNA technology draws great relevance, especially when clinical decision-making becomes uncertain at critical clinical junctures.

With a rich history in biotechnology, Dr. Stephan's expertise spans molecular diagnostics and therapeutic development. Notably, he was instrumental in the rise of personalized genetics and served as co-founder of Navigenics, the first consumer genomics company that developed pre-symptomatic polygenic risk assessment tools. His contributions to the field of oncology are equally impressive, being an early advisor to Guardant Health and contributing to next-generation sequencing techniques in cancer.

At Wobble, Dr. Stephan joins an esteemed team that includes Dr. Richard Hockett, Chief Medical Officer, and Dr. Han-Yu Chuang, Chief Technology Officer. Together, they form a formidable group of professionals poised to drive advancements in genomic diagnostics and personalized oncology. Dr. Richard Kuo, CEO and founder of Wobble Genomics, expressed his excitement about Dr. Stephan's appointment, stating, “His extensive experience, particularly in molecular diagnostics, is invaluable to our vision of transforming cancer care. Together, we aim to foster strategic partnerships and innovative solutions to redefine patient care standards.”

Wobble Genomics, founded at The Roslin Institute in Edinburgh by Dr. Richard Kuo, is committed to redefining cancer diagnostics using its long-read cfRNA liquid biopsy platform. Their current endeavors include clinical studies in collaboration with the National Health Service (NHS) in the UK, showcasing their commitment to cutting-edge research and impactful healthcare solutions.

For additional information on Wobble Genomics and their revolutionary approach to cancer diagnosis, visit wobblegenomics.com or follow them on LinkedIn and X.